Phage Display Technology: A Tool to Explore the Diversity of Inhibitors to Blood Coagulation Factor VIII

ABSTRACT

Hemophilia A is a X-linked bleeding disorder that is caused by the functional absence of blood coagulation factor VIII. The bleeding tendency in hemophilia A patients can be corrected by the administration of plasma-derived or recombinant factor VIII concentrates. A serious complication in hemophilia care is the development of factor VIII neutralizing antibodies (inhibitors) that arise as a consequence of factor VIII replacement therapy. The majority of factor VIII inhibitors are directed toward epitopes located within the A2, A3, and C2 domains of factor VIII. In this article, we summarize current knowledge on the epitope specificity of factor VIII inhibitors. In addition, we will discuss recent information on the molecular characteristics of human anti-factor VIII antibodies generated by phage display technology.

KEYWORD

Factor VIII - hemophilia - factor VIII inhibitors - phage display - scFv

REFERENCES

• 1 Bidwell E, Denson K W, Dike G W. Antibody nature of the inhibitor to antihemophilic globulin (factor 8).  Nature . 1966;  210 746-747
• 2 Hoyer L W. Hemophilia A.  N Engl J Med . 1994;  330 38-47
• 3 Jacquemin M G, Desqueper B G, Benhida A. Mechanism and kinetics of factor VIII inactivation: Study with an IgG4 monoclonal antibody derived from a hemophilia A patient with an inhibitor.  Blood . 1998;  92 416-506
• 4 Davies J, Van den Brink N E, Baglin T P. Primary structure of the variable domains of factor VIII antibodies obtained from inhibitor patient B cell RNA by V gene phage display technology.  Thromb Haemost . 1997;  suppl:575A (Abstract)
• 5 Van den Brink N E, Turenhout E AM, Davies J. VH domains of human inhibitors directed towards the factor VIII light chain contain an unusually large CDR3.  Haemophilia. 1998;  4 (Abstract) 230A
• 6 Van den Brink N E, Turenhout E AM, Davies J. Human antibodies with specificity for the C2 domain of factor VIII are derived from VH1 germline genes.  Blood . 2000;  95 558-563
• 7 Fulcher C A, DeGraaf Mahoney S, Roberts J R. Localization of human factor VIII inhibitor epitopes to two polypeptide fragments.  Proc Natl Acad Sci USA . 1985;  82 7728-7732
• 8 Scandella D, DeGraaf Mahoney S, Mattingly M. Epitope mapping of human factor VIII inhibitor antibodies by deletion analysis of factor VIII fragments expressed in Escherichia coli Proc Natl Acad Sci USA .  1988;  85 6152-6156
• 9 Scandella D, Gilbert G E, Shima M. Some factor VIII inhibitor antibodies recognize a common epitope corresponding to C2 domain amino acids 2248 through 2312, which overlap a phospholipid-binding site.  Blood . 1995;  86 1811-1819
• 10 Healey J F, Lubin I M, Nakai H. Residues 484-508 contain a major determinant of the inhibitory epitope in the A2 domain of human factor VIII.  J Biol Chem . 1995;  270 14505-14509
• 11 Lubin I M, Healey J F, Barrow R T. Analysis of the human factor VIII A2 inhibitor epitope by alanine scanning mutagenesis.  J Biol Chem . 1997;  272 30191-30195
• 12 Healey J F, Barrow R T, Tamim H M. Residues Glu2181-Val2243 contain a major determinant of the inhibitory epitope in the C2 domain of human factor VIII.  Blood . 1998;  92 3701-3709
• 13 Villoutreux B O, Bucher P, Hoffmann K. Molecular models for the two discoidin domains of human blood coagulation factor V.  J Molecular Models . 1998;  4 268-275
• 14 Pellerquer J-L, Gale A J, Griffin J H. Homology models of the C domains of blood coagulation factors V and VIII: A proposed membrane binding mode for FV and FVIII C2 domains.  Blood Cells Mol Dis . 1998;  15 448-461
• 15 McMullen B A, Fujikawa K, Davie E W. Locations of disulfide bonds and free cysteines in the heavy and light chain of recombinant human factor VIII (antihemophilic factor A).  Protein Sci . 1995;  4 740-746
• 16 Pratt K P, Shen B W, Fujikawa K. Structure of the C2 of human factor VIII at 1.5 Å resolution.  Nature . 1999;  402 439-442
• 17 Scandella D, Mattingly M, Prescott R. A recombinant factor VIII A2 domain polypeptide quantitatively neutralizes human inhibitor antibodies that bind to A2.  Blood . 1993;  82 1767-1775
• 18 Fijnvandraat K, Celie P HN, Turenhout E AM. A human alloantibody interferes with binding of factor IXa to the factor VIII light chain.  Blood . 1998;  91 2347-2352
• 19 Zhong D, Saenko E L, Shima M. Some human inhibitor antibodies interfere with factor VIII binding to factor IX.  Blood . 1998;  92 136-142
• 20 Lenting P J, Van de Loo P J-W, Donath M-JSH, et al. The sequence Glu1811-Lys1818 of human blood coagulation factor VIII comprises a binding site for activated factor IX.  J Biol Chem . 1996;  271 1935-1940
• 21 Prescott R, Nakai H, Saenko E L. The inhibitor antibody response is more complex in hemophilia A patients than in most nonhemophiliacs with factor VIII autoantibodies. Recombinate and Kogenate study groups.  Blood . 1997;  89 3663-3671
• 22 Foster P A, Fulcher C A, Houghten R A. Localization of the binding regions of a murine monoclonal anti-factor VIII antibody and a human anti-factor VIII alloantibody, both of which inhibit factor VIII procoagulant activity, to amino acid residues threonine351-serine365 of the factor VIII heavy chain.  J Clin Invest . 1988;  82 123-128
• 23 Tonegawa S. Somatic generation of antibody diversity.  Nature . 1983;  302 575-581
• 24 Rajewsky K. Clonal selection and learning in the antibody system.  Nature . 1996;  381 751-758
• 25 Stavnezer J. Immunoglobulin class switching.  Curr Opin Immunol . 1996;  8 199-205
• 26 Hoyer L W, Gawryl M S, De la Fuente B. Immunochemical characterization of factor VIII inhibitors. In: Hoyer LW, ed. Factor VIII Inhibitors, Progress in Clinical and Biological Research, Vol 150 New York: Liss 1988: 73-85
• 27 Fulcher C A, De Graaf Mahoney S, Zimmerman T S. FVIII inhibitor IgG subclass and FVIII polypeptide specificity determined by immunoblotting.  Blood . 1987;  69 1475-1480
• 28 Aalberse R C, van der Gaag R, van Leeuwen J. Serological aspects of IgG4 antibodies. I. Prolonged immunization results in an IgG4 restricted response.  J Immunol . 1983;  130 722-726
• 29 Cook G P, Tomlinson I M. The human immunoglobulin VH repertoire.  Immunol Today . 1995;  16 237-242
• 30 Williams S C, Winter G. Cloning and sequencing of human immunoglobulin Vλ gene segments.  Eur J Immunol . 1993;  23 1456-1461
• 31 Cox J PL, Tomlinson I M, Winter G. A directory of human germ-line Vκ segments reveals a strong bias in their usage.  Eur J Immunol . 1994;  24 827-836
• 32 Matsuda F, Ishii K, Bourvagnet P. The complete nucleotide sequence of the human immunoglobulin heavy chain variable region locus.  J Exp Med . 1998;  188 2151-2162
• 33 Marks J D, Hoogenboom H R, Bonnert T P. By-passing immunization.  Human antibodies from V-gene libraries displayed on phage. J Mol Biol . 1991;  222 581-597
• 34 Griffin H M, Ouwehand W H. A human monoclonal antibody specific for the leucine-33 (p1A1, HPA-la) form of platelet glycoprotein IIIa from a V gene phage display library.  Blood . 1995;  86 4430-4436
• 35 De Wildt M T R, Hoet R MA, Van Venrooij J W. Analysis of heavy and light chain pairings indicates that receptor editing shapes the human antibody repertoire.  J Mol Biol . 1999;  285 895-901
• 36 Ohlin M, Borrebaeck C A. Characteristics of human antibody repertoires following active immune responses in vivo.  Mol Immunol . 1996;  33 583-592
• 37 Kabat E A, Wu T T, Parry H M, Gottesman K E, Foeller C. Sequences of Immunological Interest.  ed 5. Bethesda, MD: U.S. Department of Health and Human Services 1991